Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Consequently, although obesity affects hundreds of millions of people globally, GLP-1 therapies currently reach only a small fraction of eligible patients, underscoring the substantial unmet need for more convenient, scalable, and accessible treatment options
Lilly ha anunciado que la Administracin de Alimentos y Medicamentos de EEUU (FDA, por sus siglas en ingls) ha aprobado la comercializacin de orforglipron (comercializado en EEUU como Foundayo) para adultos con obesidad o con sobrepeso que tambin tienen problemas de salud relacionados con el peso
Healthcare providers can assess individual risk factors, recommend appropriate supplementation, and monitor progress
43 GhouiliI.BahdoudiS.MorinF.AmriF.HamdiY.ColyP
Transform Your Vitality
US$ 22.35
US$ 23.90
US$ 26.39
US$ 24.38
US$ 22.93
